ROVI: ACUERDA CON LA FDA INICIAR UN ENSAYO CLÍNICO DE UNA NUEVA FORMULACIÓN TRIMESTRAL DE LETROZOL ISM (ANÁLISIS BANCO SABADELL)
Acaba de anunciar que, tras diversas conversaciones mantenidas con la FDA, ha decidido iniciar el desarrollo clínico de una nueva formulación trimestral (Letrozol LEBE) frente a la formulación anual inicialmente prevista de Letrozol ISM (inyectable de larga duración para el cáncer de mama hormonodependiente; 18% P.O.) frente a la administración de dosis orales diarias de Femara.Laboratorios Farmaceuticos Rovi is engaged in the sale of its own pharmaceutical products and the distribution of other products for which it holds licenses granted by other laboratories for specific periods, in accordance with the terms and conditions contained in the agreements entered into with said laboratories.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.